Market Cap 847.35M
Revenue (ttm) 568.09M
Net Income (ttm) 22.73M
EPS (ttm) N/A
PE Ratio 14.00
Forward PE 13.64
Profit Margin 4.00%
Debt to Equity Ratio 1.16
Volume 379,700
Avg Vol 484,152
Day's Range N/A - N/A
Shares Out 83.16M
Stochastic %K 32%
Beta 0.72
Analysts Strong Sell
Price Target $14.80

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted...

Industry: Medical Devices
Sector: Healthcare
Phone: 919 474 6700
Address:
4721 Emperor Boulevard, Suite 100, Durham, United States
farcanal
farcanal May. 6 at 11:52 AM
$BVS https://ir.bioventus.com/news-releases/news-release-details/bioventus-reports-first-quarter-financial-results-2 ✅ Q1 reported revenue of $132.1 million increased 7% ✅ First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share ✅ Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period ✅ Cash from operations of $8.9 million increased $28.3 million compared to the $19.3 million cash outflow in the prior-year period ✅ Company raises Non-GAAP EPS* and Cash from Operations guidance and reaffirms revenue guidance for full year 2026
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:52 AM
$BVS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.05 up 225.00% YoY • Reported revenue of $132.09M up 6.63% YoY
1 · Reply
farcanal
farcanal May. 6 at 11:45 AM
$BVS And tripled again! What a great turnaround this has been. Q1 revenue up 7%
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 12:29 PM
$BVS Share Price: $9.87 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.78 – $2.20 Target Zone: $2.95 – $3.60 Potential Upside: 56% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
History101
History101 Apr. 25 at 6:30 PM
$BVS 441 watching 4/25/2026
0 · Reply
Doozio
Doozio Apr. 23 at 7:28 PM
$BVS Thursday 🐑 🎁 s
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 9:59 PM
$BVS RSI: 73.97, MACD: 0.2825 Vol: 0.41, MA20: 9.17, MA50: 8.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Doozio
Doozio Apr. 14 at 2:23 AM
$BVS out of the tightness ONTO 🐒🍌🧠⏰♾️
0 · Reply
Valuebuilder
Valuebuilder Mar. 17 at 9:47 PM
$BVS Definitely a stock to watch for 2026 as it’s hugely undervalued.Good team in place with a diversified group of products but a complicated story.For the revenue ,margin profile and profitability it’s very cheap on every metric.Has not been discovered by the larger funds yet but when it starts getting attention it can run .
0 · Reply
ClaraDevlin_
ClaraDevlin_ Mar. 6 at 8:42 PM
$BVS value area.
0 · Reply
Latest News on BVS
Bioventus reports Q1 EPS 15c, consensus 7c

2026-05-07T06:30:12.000Z - 6 days ago

Bioventus reports Q1 EPS 15c, consensus 7c


Bioventus Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 7 days ago

Bioventus Earnings Call Transcript: Q1 2026


Bioventus Reports First Quarter Financial Results

May 6, 2026, 7:30 AM EDT - 7 days ago

Bioventus Reports First Quarter Financial Results


Bioventus initiated with an Outperform at CJS Securities

2026-03-27T13:00:51.000Z - 6 weeks ago

Bioventus initiated with an Outperform at CJS Securities


Bioventus management to meet with Barrington

2026-03-09T18:55:09.000Z - 2 months ago

Bioventus management to meet with Barrington


Bioventus price target raised to $16 from $15 at Craig-Hallum

2026-03-06T14:05:43.000Z - 2 months ago

Bioventus price target raised to $16 from $15 at Craig-Hallum


Bioventus price target raised to $14 from $13 at Barrington

2026-03-06T12:35:37.000Z - 2 months ago

Bioventus price target raised to $14 from $13 at Barrington


Bioventus Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 2 months ago

Bioventus Earnings Call Transcript: Q4 2025


Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c

2026-03-05T12:21:28.000Z - 2 months ago

Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c


Bioventus reports Q4 EPS 24c, consensus 22c

2026-03-05T12:13:21.000Z - 2 months ago

Bioventus reports Q4 EPS 24c, consensus 22c


Bioventus initiated with an Outperform at Barrington

2026-02-09T13:00:47.000Z - 3 months ago

Bioventus initiated with an Outperform at Barrington


Bioventus Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 6 months ago

Bioventus Earnings Call Transcript: Q3 2025


Bioventus reports Q3 EPS 15c vs 5c last year

2025-11-04T12:41:02.000Z - 6 months ago

Bioventus reports Q3 EPS 15c vs 5c last year


Bioventus sees FY25 EPS 64c-68c

2025-11-04T12:40:38.000Z - 6 months ago

Bioventus sees FY25 EPS 64c-68c


Bioventus Reports Third Quarter Financial Results

Nov 4, 2025, 7:30 AM EST - 6 months ago

Bioventus Reports Third Quarter Financial Results


Bioventus Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Bioventus Earnings Call Transcript: Q2 2025


Bioventus reports Q2 EPS 21c, consensus 20c

2025-08-06T11:15:44.000Z - 10 months ago

Bioventus reports Q2 EPS 21c, consensus 20c


Bioventus sees FY25 EPS 64c-68c, consensus 66c

2025-08-06T11:15:32.000Z - 10 months ago

Bioventus sees FY25 EPS 64c-68c, consensus 66c


Bioventus Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Bioventus Reports Second Quarter Financial Results


Bioventus enters $400M senior secured credit agreement

2025-08-04T12:15:21.000Z - 10 months ago

Bioventus enters $400M senior secured credit agreement


Bioventus initiated with an Overweight at Cantor Fitzgerald

2025-07-07T10:11:52.000Z - 11 months ago

Bioventus initiated with an Overweight at Cantor Fitzgerald


Bioventus management to meet with Craig-Hallum

2025-06-18T19:30:34.000Z - 11 months ago

Bioventus management to meet with Craig-Hallum


Bioventus Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q1 2025


Bioventus reports Q1 EPS 8c, consensus 2c

2025-05-06T11:36:41.000Z - 1 year ago

Bioventus reports Q1 EPS 8c, consensus 2c


Bioventus sees FY25 EPS 64c-68c, consensus 66c

2025-05-06T11:36:02.000Z - 1 year ago

Bioventus sees FY25 EPS 64c-68c, consensus 66c


Bioventus Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q4 2024


Bioventus Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings Call Transcript: Q3 2024


Bioventus Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q2 2024


Bioventus Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q1 2024


Bioventus Earnings Call Transcript: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q4 2023


Bioventus Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings Call Transcript: Q3 2023


Bioventus to Present at the Cantor Global Healthcare Conference

Sep 19, 2023, 9:52 PM EDT - 2 years ago

Bioventus to Present at the Cantor Global Healthcare Conference


Bioventus Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q2 2023


Bioventus Completes Divestiture of its Wound Business

May 23, 2023, 7:30 AM EDT - 3 years ago

Bioventus Completes Divestiture of its Wound Business


Bioventus Earnings Call Transcript: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q1 2023


Bioventus Announces Divestiture of its Wound Business

May 10, 2023, 9:00 AM EDT - 3 years ago

Bioventus Announces Divestiture of its Wound Business


Bioventus Announces CEO Leadership Change

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Bioventus Announces CEO Leadership Change


Bioventus Earnings Call Transcript: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q4 2022


farcanal
farcanal May. 6 at 11:52 AM
$BVS https://ir.bioventus.com/news-releases/news-release-details/bioventus-reports-first-quarter-financial-results-2 ✅ Q1 reported revenue of $132.1 million increased 7% ✅ First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share ✅ Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period ✅ Cash from operations of $8.9 million increased $28.3 million compared to the $19.3 million cash outflow in the prior-year period ✅ Company raises Non-GAAP EPS* and Cash from Operations guidance and reaffirms revenue guidance for full year 2026
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:52 AM
$BVS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.05 up 225.00% YoY • Reported revenue of $132.09M up 6.63% YoY
1 · Reply
farcanal
farcanal May. 6 at 11:45 AM
$BVS And tripled again! What a great turnaround this has been. Q1 revenue up 7%
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 12:29 PM
$BVS Share Price: $9.87 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.78 – $2.20 Target Zone: $2.95 – $3.60 Potential Upside: 56% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
History101
History101 Apr. 25 at 6:30 PM
$BVS 441 watching 4/25/2026
0 · Reply
Doozio
Doozio Apr. 23 at 7:28 PM
$BVS Thursday 🐑 🎁 s
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 9:59 PM
$BVS RSI: 73.97, MACD: 0.2825 Vol: 0.41, MA20: 9.17, MA50: 8.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Doozio
Doozio Apr. 14 at 2:23 AM
$BVS out of the tightness ONTO 🐒🍌🧠⏰♾️
0 · Reply
Valuebuilder
Valuebuilder Mar. 17 at 9:47 PM
$BVS Definitely a stock to watch for 2026 as it’s hugely undervalued.Good team in place with a diversified group of products but a complicated story.For the revenue ,margin profile and profitability it’s very cheap on every metric.Has not been discovered by the larger funds yet but when it starts getting attention it can run .
0 · Reply
ClaraDevlin_
ClaraDevlin_ Mar. 6 at 8:42 PM
$BVS value area.
0 · Reply
d_risk
d_risk Mar. 5 at 4:02 PM
$BVS - Bioventus Inc - 10K - Updated Risk Factors BVS overhauled 10-K risks: streamlined financing language; added EGC-to-large issuer, cash concentration, HA/CMS and broader reimbursement and ACA/Medicare cut risks; beefed up IT, cyber, supply chain, litigation, pricing pressure, talent, environmental/sterilization, privacy/export controls and IP litigation disclosures; while dropping explicit competition, branding, training, and some EU MDR detail. #MedicalDevices #HealthcareReimbursement #CybersecurityRisks #SupplyChain #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/BVS/10-K/2026-03-05
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 5 at 1:45 PM
$BVS (+8.3% pre) Bioventus Earnings Report: Q4 Overview https://ooc.bz/l/95605
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 12:49 PM
$BVS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.22 • Reported revenue of $157.9M up 2.77% YoY • Bioventus expects $2M in annual interest expense savings and extended debt maturity to July 2030 from its 2025 Credit Agreement. The broader market launch of TalisMann and StimTrial products commenced in early 2026.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 5 at 12:49 PM
$BVS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.22 • Reported revenue of $157.9M up 2.77% YoY • Bioventus Inc. expects its 2025 Credit Agreement to provide $2M in annual interest expense savings, increased liquidity, and extended debt maturity to July 2030, enhancing future financial flexibility.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 9:42 PM
$BVS Current Stock Price: $8.80 Contracts to trade: $10.0 BVS Mar 20 2026 Call Entry: $0.36 Exit: $0.54 ROI: 49% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 9:55 PM
$BVS RSI: 60.11, MACD: 0.1391 Vol: 0.22, MA20: 8.07, MA50: 7.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Feb. 9 at 2:47 PM
$DAVE $FRMI $QUIK $BVS -- THE WSJ
0 · Reply
TickerTamer
TickerTamer Feb. 4 at 4:02 PM
$BVS is a medical device company (Bioventus Inc.) focused on orthobiologics; it is navigating commercial execution challenges and a heavy debt load.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 12:56 AM
$BVS Current Stock Price: $7.93 Contracts to trade: $7.5 BVS Feb 20 2026 Call Entry: $0.81 Exit: $1.50 ROI: 86% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalShield
CapitalShield Dec. 25 at 3:21 PM
$BVS Macro forces may influence direction, yet internal execution remains the decisive factor. Margin stability needs to accompany any growth acceleration. A series of confirmed wins might reduce the required risk premium. Over time, credibility will hinge on repeatable performance.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:20 AM
$BVS Share Price: $7.21 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.66 – $0.81 Target Zone: $1.12 – $1.37 Potential Upside: 60% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply